118
Participants
Start Date
December 9, 2021
Primary Completion Date
December 30, 2022
Study Completion Date
December 30, 2022
Lorlatinib
"No treatment will be administered to the patient as an active treatment of this study. Only retrospective data about the patients treated in the compassion use program of Lorlatinib will be collected. The information below is related to Lorlatinib, target drug for the collection of data.~Lorviqua 25 mg film-coated tablets.The recommended dose is 100 mg lorlatinib taken orally once daily. Treatment with lorlatinib is recommended as long as the patient is deriving clinical benefit from therapy without unacceptable toxicity. Dosing interruption or dose reduction may be required based on individual safety and tolerability.Lorlatinib should be permanently discontinued if the patient is unable to tolerate the 50 mg dose taken orally once daily."
Hospital Puerta del Mar, Cadiz
Complejo Hospitalario Universitario A Coruña, A Coruña
Centro Oncológico de Galicia, A Coruña
Hospital Clínico Santiago, Santiago de Compostela
Hospital Dr. Josep Trueta, Girona
Hospital Universitario de Jaén, Jaén
Complejo Asistencial Universitario de León, León
Hospital Gregorio Marañón, Madrid
Hospital Clínico San Carlos, Madrid
Hospital 12 De Octubre, Madrid
Hospital Puerta de Hierro, Madrid
Hospital Fundación de Alcorcón, Madrid
Hospital Universitario Central de Asturias, Oviedo
Hospital Universitario Insular de Gran canaria, Las Palmas de Gran Canaria
Hospital Virgen del Rocio, Seville
Complejo Hospitalario de Toledo, Toledo
Hospital Universitari i Politécnic La Fe, Valencia
Hospital Clínico de Valencia, Valencia
Hospital General de Valencia, Valencia
Hospital Clínico Lozano Blesa, Zaragoza
Hospital Germans Trias i Pujol, Badalona
Hospital del Mar, Barcelona
Hospital Universitari Quiron Dexeus, Barcelona
Hospital Clinic de Barcelona, Barcelona
Hospital Universitario de Burgos, Burgos
Fundación GECP
OTHER